CTRI/2023/07/055525尚未招募Unknown
A three-arm, parallel group, double-blind, placebo-controlled, randomized trial of two doses ofantenatal corticosteroids for women with a high probability of birth in the late preterm period inhospitals in low-resource countries to improve newborn outcomes: Impact on equity, poverty, andcost-effectiveness analysis (EQUIFINANCE ACTION-III) - EQUIFINANCE ACTION-III
Translational Health Science and Technology Institute0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •The study population includes pregnant women coming to the hospital for delivery in the late preterm period (enrolled in the main ACTION III trial) and their newborn.
排除标准
- 未提供
研究者
相似试验
未知
3 期
A Double-Blind, 3-Arm, Parallel Group, Placebo-and Ropinirole-Controlled Study of SPM 962 in Subjects with Parkinson's Disease Treated Concomitantly with L-dopaJPRN-jRCT2080220857Otsuka Pharmaceutical Co., Ltd.400
招募中
2 期
A randomised controlled trial of antenatal melatonin supplementation in fetal growth restriction for fetal neuroprotection.ACTRN12617001515381Monash Health336
进行中（未招募）
不适用
A parallel-group, double-blind, randomized, placebo-controlled, active comparator, multicenter study to evaluate the efficacy, safety, tolerability and pharmacokinetics of two doses of GSK232802 administered orally as monotherapy for 12 weeks in healthy postmenopausal women with moderate to extremely severe vasomotor symptoms - NDHealthy postmenopausal women with moderate to extremely severe vasomotor symptomsMedDRA version: 6.1Level: PTClassification code 10058825EUCTR2007-001295-36-ITGlaxoSmithKline Research and Development Ltd400
进行中（未招募）
不适用
A parallel-group, double-blind, randomized, placebo-controlled,active comparator, multicenter study to evaluate the efficacy,safety, tolerability and pharmacokinetics of two doses ofGSK232802 administered orally as monotherapy for 12 weeksin healthy postmenopausal women with moderate to extremelysevere vasomotor symptoms - CNA109586Treatment of moderate to extremely severe vasomotor symptoms in healthy postmenopausal womenEUCTR2007-001295-36-DEGlaxoSmithKline Research and Development Limited400
进行中（未招募）
1 期
A parallel-group, double-blind, randomized, placebo-controlled,active comparator, multicenter study to evaluate the efficacy,safety, tolerability and pharmacokinetics of two doses ofGSK232802 administered orally as monotherapy for 12 weeksin healthy postmenopausal women with moderate to extremelysevere vasomotor symptomsEstudio de grupos paralelos, aleatorizado, doble ciego, controlado con placebo y con comparador activo, multicéntrico, para evaluar la eficacia, seguridad, tolerabilidad y farmacocinética de dos dosis de GSK232802 administrado oralmente en monoterapia durante 12 semanas a mujeres postmenopáusicas sanas con síntomas vasomotores de moderados a muy intensos. - CNA109586Treatment of moderate to extremely severe vasomotor symptoms in healthy postmenopausal women.Tratamiento de síntomas vasomotores de moderados a muy intensos en mujeres postmenopáusicas sanas.EUCTR2007-001295-36-ESGlaxoSmithKline S.A.